According to this study, the incidence of major CV events was higher in the tofacitinib group (3.4%) compared to TNF inhibitors group (2.5%), the most common of which being nonfatal myocardial infarction for tofacitinib and nonfatal stroke with TNF inhibitors, in particular for patients 65 years of age or older (155). This evidence concerns the gene TNF and myocardial infarction.